Trial Profile

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 28 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Mar 2025 According to Incyte media release, data from this study will be submitted for presentation at upcoming scientific meetings.
17 Mar 2025 According to Incyte media release, primary endpoint (Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response (HiSCR)) has been met, at both tested doses (45 mg and 75 mg).
17 Mar 2025 According to Incyte media release, data from this study will support planned regulatory submission for povorcitinib in hidradenitis suppurativa (HS) worldwide.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com